Salvage radical prostatectomy results in better functional outcomes and has a low risk of major complications as compared to those previously reported, a study claims. Furthermore, robotic salvage radical prostatectomy appears to reduce anastomotic stricture, blood loss and hospital stay, and improve continence outcomes.
Men with metastatic castration-resistant prostate cancer (mCRPC) derived significantly greater clinical benefit from cabazitaxel vs the androgen receptor-targeted agents (ARTA) abiraterone or enzalutamide, according to the results of the CARD* trial presented at ESMO 2019.
A higher Genomic Prostate Score (GPS) is a predictor of an increased risk of adverse pathology in patients who undergo radical prostatectomy after a period on active surveillance, as in those who undergo immediate prostatectomy, reports a study. The GPS is also associated with biochemical recurrence after radical prostatectomy.
There appears to be no pressing need for men with prostate cancer to undergo radiotherapy immediately after surgery, according to a recent study presented at the 2019 Congress of the European Society of Medical Oncology (ESMO 2019).
Testosterone replacement therapy (TRT) in men with hypogonadism was associated with an increased risk of ischaemic stroke, transient ischaemic attack (TIA), and myocardial infarction (MI), particularly in the first 2 years of use, a study shows.
Cabozantinib was no better than the combination of mitoxantrone and prednisone for pain relief in heavily pretreated men with metastatic castration-resistant prostate cancer (mCRPC) and symptomatic bone metastases, according to the findings of the COMET-2* trial.
Adding a LAMA* to the double combination therapy of ICS** plus LABA*** in a single inhaler improves lung function and reduces exacerbations in patients whose asthma is inadequately controlled with the combination treatment, according to the TRIMARAN and TRIGGER# studies presented at ERS 2019.
Final overall survival (OS) results from the double-blind phase III FLAURA study reinforce osimertinib as the standard frontline treatment for epidermal growth factor receptor-mutated (EGFRm) non–small cell lung cancer (NSCLC), say leading oncologists at ESMO 2019.
Babies born to mothers exposed to high levels of bisphenol A during pregnancy are at a greater risk of wheezing and poor lung function, according to a new study presented at the recently concluded International Congress of the European Respiratory Society (ERS 2019).